BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9764809)

  • 1. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
    Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
    Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
    Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
    J Cutan Pathol; 1998 Apr; 25(4):204-9. PubMed ID: 9609139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
    Hofbauer GF; Schaefer C; Noppen C; Böni R; Kamarashev J; Nestle FO; Spagnoli GC; Dummer R
    Am J Pathol; 1997 Dec; 151(6):1549-53. PubMed ID: 9403705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
    Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
    Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi.
    Itakura E; Huang RR; Wen DR; Paul E; Wünsch PH; Cochran AJ
    Mod Pathol; 2008 Mar; 21(3):326-33. PubMed ID: 18204435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
    Clarkson KS; Sturdgess IC; Molyneux AJ
    J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
    Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
    Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
    Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
    Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45.
    Shidham VB; Qi DY; Acker S; Kampalath B; Chang CC; George V; Komorowski R
    Am J Surg Pathol; 2001 Aug; 25(8):1039-46. PubMed ID: 11474288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.
    Shidham VB; Qi D; Rao RN; Acker SM; Chang CC; Kampalath B; Dawson G; Machhi JK; Komorowski RA
    BMC Cancer; 2003 May; 3():15. PubMed ID: 12735792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical investigation of PNL2 reactivity of canine melanocytic neoplasms and comparison with Melan A.
    Giudice C; Ceciliani F; Rondena M; Stefanello D; Grieco V
    J Vet Diagn Invest; 2010 May; 22(3):389-94. PubMed ID: 20453212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression.
    Strohal R; Mosser R; Kittler H; Wolff K; Jansen B; Brna C; Stingl G; Pehamberger H
    Melanoma Res; 2001 Oct; 11(5):543-8. PubMed ID: 11595894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas.
    Nicotra MR; Nisticò P; Mangoni A; Di Filippo F; Marincola FM; Natali PG
    J Immunother; 1997 Nov; 20(6):466-9. PubMed ID: 9409452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45.
    Heegaard S; Jensen OA; Prause JU
    Melanoma Res; 2000 Aug; 10(4):350-4. PubMed ID: 10985669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contribution of monoclonal antibody HMB45 in the histopathologic diagnosis of melanoma].
    Pluot M; Joundi A; Grosshans E
    Ann Dermatol Venereol; 1990; 117(10):691-9. PubMed ID: 1705764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas.
    Fetsch PA; Cormier J; Hijazi YM
    J Immunother; 1997 Jan; 20(1):60-4. PubMed ID: 9101414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
    Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
    Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients.
    Abrahamsen HN; Steiniche T; Nexo E; Hamilton-Dutoit SJ; Sorensen BS
    J Mol Diagn; 2003 Feb; 5(1):34-41. PubMed ID: 12552078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
    Mehregan DR; Hamzavi I
    Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
    de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
    J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.